Under construction – not a live service
Sign in
Taking people in FranceNo phase

Follows adults with systemic sclerosis over 5 years using blood and tissue samples

Follows adults with systemic sclerosis, a rare connective tissue disease, over 5 years.

Plain-language title generated from the registry record
Registry title: Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre

Key facts

Where
Bordeaux, FranceSee the site

Where in France

  • CHU de Bordeaux - service de rhumatologieBordeaux, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital, Bordeaux
Trial code
NCT04265144
Record updated
4 September 2025
Original description
Systemic sclerosis (SSc) is a rare form of connective tissue disease characterized by vascular involvement and the intensity of fibrosis. The lack of available treatment is largely due to the very fragmented understanding of the pathophysiology of SSc. However, one of the keys to conducting quality research on this disease remains the development of well-documented patient cohorts with reliable biological samples. The main objective of this cohort is to study the natural progression of SSc in a cohort of patients followed over 5 years.Read full original descriptionShow less

Cohort of Patients With Systemic Sclerosis and Associated Biological Collection Within the Framework of the RESO Reference Centre for Rare Systemic Autoimmune Diseases

Systemic sclerosis (SSc) is a rare form of connective tissue disease characterized by vascular involvement and the intensity of fibrosis. The lack of available treatment is largely due to the very fragmented understanding of the pathophysiology of SSc. However, one of the keys to conducting quality research on this disease remains the development of well-documented patient cohorts with reliable biological samples. The main objective of this cohort is to study the natural progression of SSc in a cohort of patients followed over 5 years.

Inclusion: Patient over 18 years old; Patient with systemic scleroderma according to the ACR/EULAR 2013 criteria, or with a " very early systemic sclerosis " defined by the presence of Raynaud's phenomenon and auto-antibodies in blood sample (ACAN positivity (≥1/160) with anti-Scl70, anti-centromere or anti-ARNPolIII specificity); Person affiliated or benefiting from a social security scheme; Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research).

Exclusion: Pregnant or breastfeeding woman; Patient under guardianship, curatorship or any other legal protection regime.

ClinicalTrials.gov NCT04265144